AI News Sentiment & Analysis
Spyre Therapeutics, Inc. (SYRE) — AI News Sentiment & Analysis
5 recent AI analyses of Spyre Therapeutics, Inc. (SYRE) stock news and press releases, with sentiment and confidence scoring updated continuously.
Spyre Announces Positive Phase 2 SKYLINE Part A Data for SPY003 in Ulcerative Colitis
BullishClinical ResultsPhase 2 SKYLINE Part A induction results for SPY003 meeting primary endpoint. (Timing: 2027 topline induction data for Part B)Sep 9, 2026Spyre Therapeutics Reports Positive Phase 2 SPY002 Clinical Trial Results for Ulcerative Colitis
BullishClinical ResultsPositive Phase 2 Part A induction results for SPY002, demonstrating statistically significant and clinically meaningful outcomes in ulcerative colitis patients. (Timing: Immediate market impact at open, with further catalysts expected from Part B enrollment and SPY003 data readout in Q3.)Jun 15, 2026Spyre Therapeutics Completes Enrollment for Key Phase 2 Clinical Trial, Paving Way for Q3/Q4 2026 Data Readouts
BullishClinical ResultsCompletion of patient enrollment for all sub-studies of the SKYWAY Phase 2 trial (SPY072), which enables topline data readouts in Q3 2026 (RA) and Q4 2026 (PsA and axSpA). (Timing: Q3 2026 and Q4 2026)Jun 3, 2026Spyre Therapeutics Accelerates Rheumatoid Arthritis Sub-Study Readout to Q3 2026
BullishThe accelerated topline data readout for the SKYWAY Rheumatoid Arthritis sub-study. This event will provide critical proof-of-concept data for SPY072 in rheumatic disease. (Timing: Q3 2026)Mar 16, 2026Spyre Therapeutics Reports Strong Cash Position and On-Track Phase 2 Trial Progress
BullishThe primary catalyst is the successful execution and positive data readouts from six proof-of-concept segments across the SKYLINE and SKYWAY Phase 2 trials in 2026. These represent critical de-risking events for the company's lead drug candidates. (Timing: Beginning Q2 2026, with further readouts throughout 2026.)Feb 19, 2026
Want the full picture?
These are AI analyses of recent press releases. Sign up to see full reasoning, confidence details, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Spyre Therapeutics, Inc. (SYRE) bullish or bearish right now?
AI Sentiment on SYRE: 5 Bullish.
What was the latest AI analysis for Spyre Therapeutics, Inc. (SYRE)?
The latest analysis was published on 9/9/2026 with the headline: "Spyre Announces Positive Phase 2 SKYLINE Part A Data for SPY003 in Ulcerative Colitis".
How does Bekodia analyze Spyre Therapeutics, Inc. (SYRE) stock?
Bekodia uses advanced AI models to process Spyre Therapeutics, Inc. (SYRE) press releases and news in real-time, extracting sentiment, confidence scores, and key catalysts while filtering out market noise.